Health
Anakinra shows therapeutic potential in critically ill COVID-19 patients – News-Medical.Net
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill COVID-19…
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill coronavirus disease 2019 (COVID-19) patients. Their findings suggest that treatment with an interleukin-1 (IL-1) receptor antagonist, anakinra, can improve the clinical output of severe COVID-19 patients. The study is currently available on the medRxiv* preprint server.
Background
Since the emergence of the COVID-19 pandemic caused by severe…
-
Noosa News6 hours agoMotorcyclist dies in crash with truck
-
Noosa News5 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News20 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General20 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate